Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome

Fig. 5

Overall survival of MDS patients stratified by the expressions of HOXB-AS3. a OS in the NTUH MDS training cohort stratified into 4 groups: HOXB-AS3 expression highest, intermediate high, intermediate low and lowest groups. b OS in the NTUH MDS training cohort stratified into 2 groups: HOXB-AS3 expression higher group (HOXB-AS3 expression highest group in Fig. 5a) and lower group (HOXB-AS3 expression lowest, intermediate low, and intermediate high groups in Fig. 5a). c OS in the NTUH MDS validation cohort stratified into 2 groups as Fig. 5b. The patients were stratified by the expressions of transcript cluster: TC17002858.hg.1 on Affymetrix GeneChip® HTA 2.0 arrays

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us